IGC
IGC Pharma, Inc.Company Information
- Company Name
- IGC Pharma, Inc.
- CIK
- CIK0001326205
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- IGC: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- IGC
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-09-25
- Last sale
- —
- Shares purchased (TTM)
- 588,235
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 5,194,882
- Shares outstanding
- 100,331,320
- Ownership
- 5.18%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 0.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 3 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Inventory Net | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | ||||||
| Short Term Investments | 0 | 0 | 0 | - | - | - | - | - | 0 | - | 0 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 6 | ||||||
Assets Noncurrent | |||||||||||||||||
| Intangible Assets Net Excluding Goodwill | 6 | 5 | 5 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 8 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Noncurrent | 8 | 8 | 8 | 6 | 6 | 6 | 6 | 6 | 6 | 8 | 10 | ||||||
| Assets | 9 | 9 | 10 | 8 | 9 | 9 | 10 | 11 | 10 | 11 | 17 | ||||||
Liabilities Current | |||||||||||||||||
| Accounts Payable Current | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | - | ||||||
| Loans Payable Current | 1 | 1 | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | ||||||
Liabilities Noncurrent | |||||||||||||||||
| Long Term Debt Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Notes Payable | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 2 | ||||||
| Commitments And Contingencies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
Stockholders Equity | |||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stocks Including Additional Paid In Capital | 142 | 139 | 136 | 132 | 131 | 129 | 129 | 127 | 124 | 123 | 123 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -6 | -6 | -5 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | ||||||
| Retained Earnings Accumulated Deficit | -130 | -127 | -123 | -122 | -121 | -120 | -118 | -116 | -114 | -111 | -105 | ||||||
| Stockholders Equity | 6 | 6 | 8 | 6 | 6 | 6 | 7 | 8 | 7 | 9 | 14 | ||||||
| Liabilities And Stockholders Equity | 9 | 9 | 10 | 8 | 9 | 9 | 10 | 11 | 10 | 11 | 17 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 600 | 600 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 102 | 99 | 92 | 84 | 81 | 78 | 77 | 76 | 67 | 64 | 64 | ||||||
| Shares Outstanding | 102 | 99 | 92 | 84 | 81 | 78 | 77 | 76 | 67 | 64 | 64 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialIGC Pharma, Inc. (IGC) — SEC Financial Statements & Analysis
IGC Pharma, Inc. (IGC) is a pharmaceutical preparations company, incorporated in MD. IGC Pharma, Inc. trades on NYSE as: IGC. IGC Pharma, Inc. (IGC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, IGC Pharma, Inc. carries a market cap of $27.09M, a P/E ratio of -3.09x, a P/B ratio of 4.42x, a P/S ratio of 24.60x, an enterprise value of $27.84M, and an EV/EBITDA multiple of -2.95x. On profitability, it posts a gross margin of 32.33%, an operating margin of -912.44%, a net margin of -795.46%, a Return on Equity (ROE) of -140.56%, a Return on Assets (ROA) of -96.01%, and a Return on Invested Capital (ROIC) of -154.68%. Per share, it reports EPS of $-0.09, diluted EPS of $-0.09, free cash flow per share of $-0.07, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -13.38% year-over-year, net income growth of 22.99% year-over-year, and EPS growth of -6.20% year-over-year. On the balance sheet, it maintains a current ratio of 0.39x, a quick ratio of 0.13x, working capital of $-1.95M, a debt-to-equity ratio of 0.55x, a debt ratio of 0.35, free cash flow of $-7.05M (TTM), and net debt of $751.00K. Figures sourced from SEC EDGAR.
- Market Cap
- $27.09M
- P/E TTM
- -3.09x
- EPS TTM
- $-0.09
- P/B TTM
- 4.42x
- ROE TTM
- -140.56%
- ROA TTM
- -96.01%
- Debt To Equity
- 0.55x
- Free Cash Flow TTM
- $-7.05M
- Net Revenue TTM Growth 1Y
- -13.38%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is IGC Pharma, Inc. in?
IGC Pharma, Inc. (IGC) operates in the Pharmaceutical Preparations industry.
What exchange does IGC trade on?
IGC Pharma, Inc. (IGC) trades on the NYSE.
Where is IGC Pharma, Inc. incorporated?
IGC Pharma, Inc. is incorporated in MD.
When was IGC Pharma, Inc. (IGC)'s most recent SEC filing?
IGC Pharma, Inc. (IGC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is IGC's market cap?
IGC Pharma, Inc. (IGC) has a market capitalization of $27.09M as of 2026-06-30.
What is IGC's EPS (earnings per share)?
IGC Pharma, Inc. (IGC)'s trailing twelve month EPS is $-0.09 as of 2026-06-30.
What is IGC's ROE (return on equity)?
IGC Pharma, Inc. (IGC)'s trailing twelve month Return on Equity (ROE) is -140.56% as of 2026-06-30.
What is IGC's ROA (return on assets)?
IGC Pharma, Inc. (IGC)'s trailing twelve month Return on Assets (ROA) is -96.01% as of 2026-06-30.
What is IGC's ROIC (return on invested capital)?
IGC Pharma, Inc. (IGC)'s trailing twelve month Return on Invested Capital (ROIC) is -154.68% as of 2026-06-30.
What is IGC's EV/EBITDA?
IGC Pharma, Inc. (IGC)'s trailing twelve month EV/EBITDA is -2.95x as of 2026-06-30.